Biotech stocks in the U.S. have outperformed significantly over the last three years -- and this can continue, says Matthew Roden, executive director of biotechnology equity research at UBS AG.» Read More
CNBC's Meg Tirrell, and Sam Waksal, Kadmon founder & chairman, discuss plans to take the biotech company public.
Dr. George Scangos, Biogen Idec CEO, discusses new therapies in multiple sclerosis, Alzheimer's disease and pain.
Anne Wojcicki, co-founder and CEO of genetic-testing startup 23andMe, discusses the new deals with Pfizer and Genentech.
CNBC's Meg Tirrell speaks to Robert Hugin, Celgene chairman & CEO, about the company's ambitious long-term guidance and broad-based drug pipeline.
CNBC's Meg Tirrell speaks to John Lechleiter, Eli Lilly CEO, about the strength and outlook for the health care sector, and what new drugs he's most excited about.
CNBC's Meg Tirrell provides insight to the debate over transparency from biotech companies. Biotech investor Brad Loncar, thinks this is just an awareness issue.
The biotechs were one of the best performing sectors for 2014. Can it work wonders for 2015? Cramer gives his top players in the biotech space.
A total of 71 biotech companies went public in 2014. Cowen Group President and Cowen & Company CEO Jeffrey Solomon, discusses the market sentiment toward the sector.
Discussing the outlook on the pharmaceutical sector, including leaders like Gilead and Celgene, with Michael Yee, RBC Capital Markets biotech analyst.
Gilead Sciences is lifting the biotech sector higher in today's trade, reports CNBC's Meg Tirrell.
Biotech finished 2014 up 44 percent. David Seaburg, thinks biotech will outperform the S&P 500 this year, but there could be some suffering mid-year.
IPO momentum should continue into 2015 after an active 2014 when huge offerings hit like "mammoths from the sky," an analyst said.
CNBC's Dominic Chu takes a look at the biggest winners of the market rally and digs into the massive year-end surge for small caps.
Eric Schmidt, Cowen & Company senior analyst, predicts the biotech sector will outperform the S&P 500 next year.
CNBC's Meg Tirrell provides insight to the selloff in biotech stocks after Express Scripts announced it will exclusively cover AbbVie's hepatitis C drug.
Brewing price sensitivity in the sector, compounded with expensive valuations, led to the selloff in U.S. biotech stocks, says Peter Boockvar, Chief Market Analyst at The Lindsey Group.
Express Scripts' decision to drop Gilead's Sovaldi treatment sparked fears that pharmaceutical firms may have to bow to pricing pressure moving forward, says Andrew McDonald, Co-Portfolio Manager at BioShares Funds.
CNBC's Bob Pisani is tracking the action in biotech stocks into the end of the year. CNBC's Bertha Coombs, provides perspective.
After Express Scripts exclusively selected AbbVie over Gilead and JNJ for its hepatitis C drug, CNBC's Meg Tirrell discusses how the news has impacted the entire biotech industry.
Mark Fisher, MBF Clearing Corp. chairman, shares his favorite stock in the biotech space.